Diyabetik Ketoasidozlu Hastaya Yaklaşım

Authors

Eşref Araç
Ömer Faruk Alakuş

Synopsis

Diabetic ketoacidosis (DKA) is a severe acute complication of diabetes characterized by hyperglycemia and metabolic acidosis, occurring mostly in type 1 diabetes as well as under extreme stress conditions. It is commonly triggered by infections, interruptions or errors in insulin therapy, dietary non-compliance, and certain medications, although no cause is identified in twenty percent of cases. Symptoms and clinical signs develop within 24 hours and include polydipsia, polyuria, nausea, abdominal pain, fruity acetone breath odor, Kussmaul breathing, and dehydration. Diagnosis is confirmed by plasma glucose exceeding 300 mg/dL, ketonemia of 3 mmol/L or more, blood pH of 7.30 or lower, and serum bicarbonate levels of 15 mEq/L or less. Differential diagnosis requires distinguishing DKA from alcoholic or starvation ketoacidosis, other high anion gap metabolic acidoses, and metabolic encephalopathy. The main therapeutic goals are to restore fluid and electrolyte deficits, normalize osmolality and blood glucose levels, eliminate ketosis, and resolve the underlying trigger. Management involves fluid replacement over 24 to 36 hours, intravenous regular insulin therapy provided serum potassium is above 3.3 mEq/L, and careful potassium monitoring and repletion. Routine bicarbonate therapy is not recommended unless blood pH drops below 7.0. DKA resolution is defined by a venous pH above 7.30, serum bicarbonate of 18 mEq/L or higher, and blood glucose under 200 mg/dL, after which subcutaneous insulin is initiated upon oral intake resumption.

References

Centers for Disease Control and Prevention, Diabetes Public Health Resource [cited 2021 Feb 10]. Available from: https://www.cdc.gov/diabetes/statistics/hospitalization_national.html

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. In: Diabetes Care . Diabetes Care; 2009 p. 1335–43.

Fulop M, Tannenbaum H, Dreyer N. KETOTIC HYPEROSMOLAR COMA. The Lancet. 1973 Sep 22;302(7830):635–9.

Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: Clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of theraphy in 37 cases1. Medicine (United States). 1972;51(2):73–94.

Morris LR, Kitabchi AE. Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoacidosis. Diabetes Care. 1980;3(1):53–6.

Shah P, Isley WL. Ketoacidosis during a Low-Carbohydrate Diet. New England Journal of Medicine. 2006 Jan 5;354(1):97–8.

Reichard GA, Owen OE, Haff AC, Paul P, Bortz WM. Ketone body production and oxidation in fasting obese humans. Journal of Clinical Investigation. 1974;53(2):508–15.

George FC. Fuel metabolism in starvation. Vol. 26, Annual review of nutrition. Annu Rev Nutr; 2006. p. 1–22.

Mahoney CA. Extreme Gestational Starvation Ketoacidosis: Case Report and Review of Pathophysiology. American Journal of Kidney Diseases . 1992;20(3):276–80.

Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Management of hyperglycemic crises in patients with diabetes . Vol. 24, Diabetes Care. American Diabetes Association Inc.; 2001. p. 131–53. Available from:

Barrett EJ, DeFronzo RA. Diabetic ketoacidosis: Diagnosis and treatment. Hospital Practice. 1984;19(4):89–104.

Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JAE, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabetic Medicine. 2011 May;28(5):508–15.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018 Nov;68(6):394–424.

Published

May 20, 2021

License

License